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Abstract
Background: Idiopathic inflammatory myopathies (IIMs) are a rare group of autoimmune syndromes characterized
by chronic muscle inflammation and muscle weakness with no known cause. Little is known about their incidence
and prevalence. This study reports the incidence and prevalence of IIMs among commercially insured and Medicare
and Medicaid enrolled populations in the US.
Methods: We retrospectively examined medical claims with an IIM diagnosis (ICD-9-CM 710.3 [dermatomyositis
(DM)], 710.4 [polymyositis (PM)], 728.81[interstitial myositis]) in the MarketScan
W databases to identify age- and
gender-adjusted annual IIM incidence and prevalence for 2004–2008. Sensitivity analysis was performed for
evidence of a specialist visit (rheumatologist/ neurologist/dermatologist), systemic corticosteroid or
immunosuppressant use, or muscle biopsy.
Results: We identified 2,990 incident patients between 2004 and 2008 (67% female, 17% Medicaid enrollees, 27%
aged ≥65 years). Overall adjusted IIM incidence for 2004–2008 for commercial and Medicare supplemental groups
combined were 4.27 cases (95% CI, 4.09-4.44) and for Medicaid, 5.23 (95% CI 4.74-5.72) per 100,000 person-years
(py). Disease sub-type incidence rates per 100,000-py were 1.52 (95% CI 1.42-1.63) and 1.70 (1.42-1.97) for DM, 2.46
(2.33-2.59) and 3.53 (3.13-3.94) for PM, and 0.73 (0.66-0.81) and 0.78 (0.58-0.97) for interstitial myositis for the
commercial/Medicare and Medicaid cohorts respectively. Annual incidence fluctuated over time with the base
MarketScan populations. There were 7,155 prevalent patients, with annual prevalence ranging from 20.62 to 25.32
per 100,000 for commercial/Medicare (83% of prevalent cases) and from 15.35 to 32.74 for Medicaid.
Conclusions: We found higher IIM incidence than historically reported. Employer turnover, miscoding and
misdiagnosing, care seeking behavior, and fluctuations in database membership over time can influence the results.
Further studies are needed to confirm the incidence and prevalence of IIM.
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Autoimmune idiopathic inflammatory myopathies (IIMs)
consist of a rare group of autoimmune syndromes charac-
terized by chronic muscle inflammation and muscle weak-
ness. They are classified as autoimmune disorders [1] and
have no known cause, although research has implicated in-
fectious agents, medications, and ultraviolet radiation in
their etiology [2]. Three main types of IIMs have been pro-
posed based on clinical and histopathologic features: (a)
polymyositis (PM), (b) dermatomyositis (DM), and (c) spor-
adic inclusion body myositis (sIBM). Recent reports have
described two new types: nonspecific myositis, and
immune-mediated necrotizing myopathy [3-5]. Older
reports [6] also describe an “interstitial myositis” that has
not been reported extensively in the literature. Dermato-
myositis is the most common of the myositis disorders [2,7].
Polymyositis is often associated with other connective tissue
disorders such as lupus [6,8,9]. Treatments for IIMs typically
consist of medications such as corticosteroids as first line
therapy, (e.g., high doses of oral or intravenous prednisone)
and immunosuppressants and immunomodulators (e.g.,
methotrexate, mycophenolate mofetil, tacrolimus, rituxi-
mab) as second line [2]. Physical therapy is also used [9].
There are few epidemiological studies on IIMs. Until
recently, many of the studies of incidence and preva-
lence of the disease have been on relatively small popu-
lation studies, often using both medical records and
muscle biopsy to ascertain the disease [8]. These types
of studies have identified annual myositis (including its
sub-types) incidence in the range of 0.1 to 1 per 100,000
person-years (py) [2,10-15].
One recent study using administrative claims data for
Quebec (approximately 7.5 million beneficiaries) estimated
prevalence of 21.5 (95% CI: 19.4, 23.9) per 100,000 patients
for dermatomyositis and polymyositis, using an IIM case
definition of ≥2 outpatient claims with an ICD-9-CM diag-
nosis recorded for either condition ≤2m o n t h sa p a r ta n d
within a 2 year time span, or ≥1 inpatient claim with either
ICD-9-CM code, as well as an alternate algorithm with one
or more billing code from a rheumatologist [16]. The
authors reported higher prevalence for women and older
patients. Other studies reporting rates by age and/or sex
also have found that incidence rates increase with age
(although dermatomyositis affects children as well as
adults) and are approximately twice as high among women
as among men [2,6-8,12]. Separate community-based epi-
demiologic studies identified a range of prevalence for IIMs,
including IIM prevalence of 5.1 per 100,000 in the U.S.
[17], PM prevalence of 3.45 per 100,000 in Olmsted
County, Minnesota, USA [10] and DM prevalence of 21.42
[18].
Recent work using an U.S. privately insured managed
care administrative claims database for 2003–2008 identi-
fied a 65/35 female to male ratio of patients with myositis
(polymyositis, dermatomyositis, or interstitial myositis) with
a median age of 49 years. The overall age- and sex-adjusted
myositis incidence rate was 6.57 cases (95% CI, 6.20–6.94)
per 100,000 py and was 3.79 for polymyositis, 1.38 for
dermatomyositis, and 1.69 for interstitial myositis per
100,000 py[19], notably higher than the 0.1 to 0.5 per
100,000 myositis incidence reported using smaller, fixed
populations [13-15]. Annual myositis prevalence identified
in the same study for the period 2003–2008 ranged from
13.99 in 2003 to 17.37 in 2008 per 100,000 py[19]. These
prevalence rates are in the range of those reported by Ber-
natsky [16] in an administrative claims database in Quebec,
suggesting prevalence of myositis, as identified in adminis-
trative claims databases, may be in the range of 14–22 cases
per 100,000 py.
The aim of the present study is to examine age and sex
adjusted incidence and prevalence of IIM using commer-
cial, Medicare and Medicaid populations. This approach
offers several advantages. First, it uses a large, geographic-
ally diverse U.S. administrative claims database. Since IIMs
are rare, the large sample available in the database allows
more robust estimates of incidence and prevalence than in
many previous studies, which examined IIM incidence
and/or prevalence in smaller populations. Second, this ap-
proach provides incidence and prevalence estimates by sex
and age group, and includes populations with diverse
payers (both commercial and Centers for Medicare & Me-
dicaid Services [CMS]). Third, this study includes out-
patient as well as inpatient claims, which limits bias in
case identification by providing greater sensitivity in inci-
dence and prevalence estimates than would be possible if
limited to hospitalization data only. Many of the published
incidence and prevalence studies of IIMs that utilized only
hospital data [8] may have under-estimated incidence and
prevalence, since myositis often does not require
hospitalization.
Methods
Study design and subject identification
Patients were selected for the study period 2004–2008
from large administrative claims databases (the Market-
Scan
W Commercial Claims and Encounters Database,
Medicare Supplemental and Coordination of Benefit
Database, and Medicaid Multi-State Database), geo-
graphically representative of the U.S. population. The
commercial database contains information for de-identi-
fied, standardized medical and outpatient pharmacy
claims data for the population under age 65 covered by
private-sector health plans (approximately 14 million
enrollees annually). Enrollees are covered under 130
unique carriers representing a variety of plan types, in-
cluding fee-for-service and capitated health plans. The
Medicare database contains healthcare experience for
1.6 million individuals (retired or working-aged) with
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The Medicaid database contains the pooled healthcare
experience of approximately 28 million Medicaid enrol-
lees representing 10 different states. Commercial and
Medicare enrollees were reported together in the same
tables, with incidence and prevalence reported for the
combined groups, as their data was contributed by the
same group of employers. Incidence and prevalence for
Medicaid enrollees were reported separately.
The MarketScan
W Databases used in this study are
de-identified and fully compliant with the Health Insur-
ance Portability and Accountability Act of 1996. Because
this study did not involve the collection, use, or trans-
mittal of individually identifiable data, Institutional Re-
view Board review or approval was not required.
Three types of IIMs were identified for dermatomyositis
(DM: ICD-9-CM 710.3), polymyositis (PM: ICD-9-CM
710.4), and interstitial myositis (ICD-6-CM 728.81), using a
combination of outpatient and inpatient medical claims (re-
ferred to as “diagnostic claims method”), since patients with
the condition may not require inpatient treatment [16].
While this method decreases specificity, the increase in sen-
sitivity provides additional insight into the potential scope
of persons seeking treatment for IIMs in the U.S. popula-
tion. Sensitivity analyses, which required criteria in addition
to diagnoses (e.g., a specialist visit, IIM medication, or a
muscle biopsy) were also performed on annual prevalence
and combined incidence (2004–2008).
The incidence date was the earliest date of service be-
tween 1/1/2004 and 12/31/2008 with a qualifying medical
claim with one of the three IIM diagnoses. A qualifying IIM
medical claim was the earliest of an inpatient claim or the
first of at least two office or ER visits (including combina-
tions) at least 30 days and less than 365 days apart. The
IIM incident cohort was identified as patients at least
18 years of age on the qualifying date of service with an
IIM diagnosis, had continuous health plan medical and
pharmacy benefits for 1 year before and 1 year after the ser-
vice date, and had no claim with an IIM diagnosis in a pre-
vious year. Incidence was reported annually and for the
combined period 2004–2008. The databases extended to
2003, with patients having any evidence of IIMs excluded
from the incidence but not excluded from the prevalence
cohort. For sensitivity analyses that required either a one
year preview or one year follow-up period after the first
IIM service date, patient data were evaluated starting in
2003 and extending through 2009.
IIM prevalence was calculated to represent the actual
burden of disease at a point of time, and was identified
similarly to incidence, except that patients were permitted
to have a previous IIM claim. Patients required a qualifying
IIM claim during the year, as well as healthplan eligibility
for the entire year, to be counted as prevalent in that year.
This method identifies prevalence of healthcare utilization
for IIM and therefore under-represents IIM prevalence in
the MarketScan databases for those patients who have the
condition but do not have a qualifying IIM claim in each
year for which they maintain healthcare eligibility. However,
the strength of this method is that it enables each year to
be evaluated separately, and does not result in an artificial
increase in prevalence that might be observed if patients
with IIM claims in an earlier year in the study continue to
contribute to prevalence counts regardless of whether they
have an IIM claim in that year.
Subject characteristics
Patients with IIMs were classified into a general group (any
m y o s i t i s )a sw e l la sa tl e a s to n es u b - g r o u p :D M ,P M ,o r
interstitial myositis. Patients could have more than one type
of myositis.
Patient age, gender, urban/rural and geographic region
(not available for Medicaid), healthplan type, race (Medic-
aid only) and payer (commercial, Medicare, Medicaid) were
identified on the date of the earliest qualifying IIM claim
for both the incident and prevalent cohorts.
Patient comorbidities were identified based on the pres-
ence of one inpatient or two or more outpatient claims with
a non-rule out ICD-9-CM diagnosis for the comorbidity of
interest in the 1 year before the incidence or prevalence
date. Medications of interest were identified from outpatient
pharmacy claims on or 1 year following the incidence or
prevalence date. For the sensitivity analyses, evidence of an
outpatient visit to a rheumatologist, dermatologist, or neur-
ologist was captured from medical claims on and 1 year fol-
lowing the index date. Two additional sensitivity criteria
were examined: evidence of a medical or outpatient phar-
macy claim for a systemic corticosteroid or immunosup-
pressant (IIM treatment)
a on or 1 year following the index
date, as well as a medical claim for muscle biopsy
b 1 year be-
fore, on, or 1 year following the index date. Sensitivity ana-
lyses were performed on the combined myositis group as
well as on the DM, PM, and interstitial myositis sub-groups.
Incidence and prevalence calculations
For each calendar year between 2004 and 2008, annual inci-
dence was calculated by dividing the number of incident
cases by the corresponding annual population at risk. Preva-
lent patients were excluded from the numerator as well as
the denominator for all incidence calculations. To qualify
for the denominators, patients had to have no previous
qualifying IIM claims, be 18 years during the calendar year
of interest, and have continuous medical and pharmacy eli-
gibility for two consecutive years, including the entire calen-
dar year of interest as well as one day in each of the
bordering years.
Incidence was also calculated for the period 2004–2008,
using the number of unique incident cases during the time
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cidence rate was the total number of person-years at risk
between 2004–2008, for a maximum possible of five
person-years for continuous enrollees 18 years or older
and with no evidence of an IIM during the period.
For comparison among different data sources, both over-
all and annual incidence rates were age- and sex-adjusted
to a U.S. standard population (2000 U.S. Census using the
following formula following Insigna et al. [20]:
nij U:S ðÞ
NU :S ðÞ
 
N MarketScan ðÞ
nij MarketScan ðÞ
w h e r eNi st h et o t a lp o p u l a t i o ni np e r s o n - t i m e( i nt h er e l e -
vant MarketScan Database or in the 2000 U.S. Census as
Table 1 Characteristics of myositis incident patients
(2004–2008)
Commercial and
Medicare patients
Medicaid patients
n% n %
Myositis (Overall)
1 2,477 100% 513 100.0%
Dermatomyositis 902 36.4% 170 33.1%
Polymyositis 1,438 58.1% 346 67.4%
Interstitial myositis 401 16.2% 75 14.6%
Year
2004 436 17.6% 190 37.0%
2005 522 21.1% 108 21.1%
2006 502 20.3% 64 12.5%
2007 555 22.4% 87 17.0%
2008 462 18.6% 64 12.5%
Age
18-24 60 2.4% 31 6.0%
25-34 123 5.0% 53 10.3%
35-44 292 11.8% 91 17.7%
45-54 558 22.5% 111 21.6%
55-64 748 30.2% 116 22.6%
65-74 392 15.8 63 12.3
75+ 304 12.3 48 9.4%
Gender
Female 1,612 65.1 397 77.4%
Male 865 34.9% 116 22.6%
Race/Ethnicity (N, %)
Caucasian .... .... 193 37.6%
African American .... .... 220 42.9%
Hispanic .... .... 25 4.9%
Other/Unknown .... .... 7 1.4%
Region
Northeast 289 11.7% .... ....
North Central 756 30.5% .... ....
South 956 38.6% .... ....
West 461 18.6% .... ....
Unknown 15 0.6% .... ....
Urbanization
Urban 2,087 84.7% .... ....
Rural 380 15.3% .... ....
Unknown 10 0.4% .... ....
Medicare 699 28.2 % 228 44.4%
Fee-for-service (N, %)
Fee-for-service 1,443 58.3% 362 70.6%
Not fee-for-service 1,034 41.7% 150 29.2%
Unknown 0 0% 1 0.2%
Clinical Conditions (365
days before index date)
Rheumatoid Arthritis 170 6.9% 51 9.9%
Table 1 Characteristics of myositis incident patients
(2004–2008) (Continued)
Commercial and
Medicare patients
Medicaid patients
n% n %
Clinical Conditions (365
days before index date)
Systemic lupus erythematosus 158 6.4% 41 8.0%
Systemic sclerosis 44 1.8% 12 2.3%
Cushing syndrome 3 0.1% 1 0.2%
Addison's disease 10 0.4% 6 1.2%
Other Inflammatory
Arthritis/Arthropathies
563 22.7% 151 29.4%
Back problems 654 26.4% 139 27.1%
Dysphagia 130 5.2% 29 5.7%
Hypertension 897 36.2% 256 49.9%
Diabetes 385 15.5 % 159 31.0%
Depression 164 6.6% 103 20.1%
Malignancy 259 10.5% 52 10.1%
Medications on or 365
days after index date
Systemic corticosteroid 1852 74.8% 321 62.6%
Topical corticosteroid 1722 69.5% 294 57.3%
Methotrexate 650 26.2% 73 14.2%
Azathioprine 352 14.2% 64 12.5%
Hydroxychloroquine 353 14.3% 51 9.9%
Intravenous immunoglobulin 24 1.0% 6 1.2%
Cyclosporine 62 2.5% 6 1.2%
Mycophenolate mofetil 136 5.5% 16 3.1%
Leflunomide 17 0.7% 5 1.0%
Thalidomide 1 0.0% 0 0.0%
Cyclophosphamide 34 1.4% 9 1.8%
Tacrolimus 50 2.0 % 5 1.0%
Rituximab 24 1.0% 2 0.4%
1Myositis subgroups were not mutually exclusive, and patients could be
assigned to more than one subgroup.
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sex strata (from the relevant MarketScan Database or the
2000 U.S. Census as indicated).
Annual prevalence was calculated by dividing the number
of prevalent cases identified in the data each year by the
number of enrollees 18 years or older during the calendar
year who had two years of continuous medical and phar-
macy eligibility, one of which spanned the entire calendar
year of interest, as well as one day in each of the bordering
years.
The same methods were applied for sensitivity analyses
for the combined 2004–2008 incidence rates and for annual
prevalence. Each of the three sen s i t i v i t yc r i t e r i aw e r ea p -
plied separately as well as combined (patients must have
had at least one of the three criteria in addition to being
identified as incident or prevalent to contribute to the nu-
merator). For the purposes of this manuscript, each of the
three sensitivity analyses as well as the three combined are
presented for 2004–2008 incidence for IIMs and the three
sub-types. For annual prevalence, only the combined
sensitivity analyses are presented, for combined IIMs only,
for which to be counted in numerator, patients must have
had at least one claim for a muscle biopsy, specialist visit,
or immunosuppressant or systemic corticosteroid in the
time periods described above, in addition to being identified
as prevalent in that year.
Statistical analyses
Confidence intervals for the crude rates and age- and
gender-adjusted rates were calculated using the normal
approximation to the binomial distribution. Uncertainty
in each yearly age- and gender- adjusted rate was calcu-
lated using basic properties of variance, treating each
yearly age- and gender-adjusted rate as a simple linear
combination of the crude age- and gender-adjusted rates
for that same year. Incidence rates were analyzed with
the GENMOD procedure in SAS 9.2 using a negative bi-
nomial error distribution, log link function, and log of
the corresponding denominator as an offset. Equality of
crude incidence rates across age groups and gender was
Table 2 Myositis incidence (2004–2008)
Commercial and Medicare supplemental database incidence
(per 100,000)
1
Medicaid database incidence
(per 100,000)
1
Crude rate Age- and Gender-
adjusted rate
4
95% CI
(adjusted rate)
Crude
rate
Age- and Gender-
adjusted rate
4
95% CI
(adjusted rate)
Myositis (Overall)
2 4.88 4.27 4.09-4.44 5.20 5.23 4.74-5.72
Dermatomyositis 1.78 1.52 1.42-1.63 1.72 1.70 1.42-1.97
Polymyositis 2.83 2.46 2.33-2.59 3.51 3.53 3.13-3.94
Interstitial myositis 0.79 0.73 0.66-0.81 0.76 0.78 0.58-0.97
Year
2004 5.37 4.52 4.07-4.96 4.27 4.47 3.80-5.15
2005 6.02 5.08 4.61-5.54 6.16 6.44 5.08-7.80
2006 5.15 4.45 4.04-4.86 5.33 5.14 3.73-6.54
2007 4.80 4.25 3.87-4.62 7.27 6.85 5.29-8.41
2008 3.66 3.38 3.06-3.71 5.11 5.08 3.70-6.45
Age (LRT χ
2 =81.73, df=6 , p<0.001)
3 (LRT χ
2 =38.69, df=6 , p<0.001)
3
18-24 1.35 1.33 0.99-1.67 2.02 1.74 1.09-2.40
25-34 2.03 1.96 1.61-2.30 3.34 3.62 2.48-4.76
35-44 3.14 3.10 2.74-3.45 6.13 5.33 4.20-6.47
45-54 4.77 4.69 4.30-5.08 7.97 7.54 6.12-8.95
55-64 6.95 6.94 6.44-7.44 10.20 9.72 7.93-11.52
65-74 9.25 9.30 8.38-10.22 5.13 4.83 3.62-6.05
75+ 7.21 7.32 6.49-8.15 3.20 3.08 2.18-3.99
Gender (LRT χ
2 =6.77, df=1, p =0.009)
3 (LRT χ
2 =9.08, df=1, p =0.003)
3
Female 5.97 5.38 5.11-5.66 5.95 6.68 6.00-7.36
Male 3.65 3.07 2.85-3.28 3.64 3.67 2.96-4.37
1Rates are per 100,000 person-years for the period from 2004–2008, except year-specific rates, which are per 100,000 individuals.
2Myositis subgroups were not mutually exclusive, and patients could be assigned to more than one subgroup.
3 Generalized linear model using negative binomial family and log link. Not adjusted for other covariates. Year-specific analysis on adjusted rates; demographic
analyses on crude rates.
4 Age and gender adjustment was done for all variables, except age distribution was gender adjusted and gender distribution was age adjusted. Rates reflect
2000 US population.
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results were calculated as described above but with the
numerators limited to the appropriate subgroup of
subjects.
Results
Incident cohort
Among nearly 50,750,000 py in the commercial/Medi-
care databases and close to 9,860,000 py in the Medicaid
database, a total of 2,990 incident cases were identified,
2,477 (83%) in the commercially insured/Medicare sup-
plemental databases and 513 (17%) in the Medicaid
database (Table 1). Among the incident cases in the
combined databases, 1,072 had DM, 1,784 had PM and
476 had interstitial myositis (patients may have had
more than one type of myositis). Females comprised
67%, with the largest share of patients in the 55–64 age
group (Table 1). Among commercially insured or Medi-
care enrolled females, the mean age was 56.3 years (SD
14.8) and among males, 57.7 years (SD 14.3). Among
Medicaid beneficiaries, the mean age was 51.6 years (SD
17.0) and 52.2 years (SD 16.4) among females and males
respectively, reflecting the younger age distribution with
the Medicaid database.
Among Medicaid beneficiaries, those with incident
IIMs were more likely to be African American (42.9%)
than Caucasian (37.6%) or Hispanic (4.9%) (Table 1).
The race/ethnicity composition of the denominator,
however, was 22.8%, 41.8%, and 19.7% respectively, indi-
cating that incidence of IIMs was disproportionately
higher among African Americans. Race was not available
for the commercial/Medicare cohort. The southern re-
gion contributed the greatest share of incident cases to
the commercial/Medicare cohort, followed by the north
central region, with nearly 85% of cases from an urban
area, but these differences reflect the overall distribution
of patients in the databases.
The most common comorbid conditions (identified in
15-36% of incident patients) among the commercial/
Medicare cohort were hypertension, back problems,
other inflammatory arthritis/arthropathies (IA/A), and
diabetes. Rates of all reported comorbid conditions were
Table 3 Sensitivity Analysis of Incidence Rates per 100,000 person-years (2004–2008)
Commercial and Medicare supplemental database Medicaid database
N Crude rate Age & Gender
adjusted rate
95% CI for
adjusted rate
N Crude
rate
Age & Gender
adjusted rate
95% CI for
adjusted rate
Base case analysis (IIMs) 2,477 4.88 4.27 4.09-4.44 513 5.20 5.23 4.74-5.72
Dermatomyositis 902 1.78 1.52 1.42-1.63 170 1.72 1.70 1.42-1.97
Polymyositis 1,438 2.83 2.46 2.33-2.59 346 3.51 3.53 3.13-3.94
Interstitial myositis 401 0.79 0.73 0.66-0.81 75 0.76 0.78 0.58-0.97
Presence of muscle biopsy one year prior to or one year following index date
IIMs 738 1.45 1.25 1.16-1.35 102 1.03 1.05 0.83-1.27
Dermatomyositis 248 0.49 0.43 0.38-0.49 34 0.34 0.34 0.22-0.46
Polymyositis 574 1.13 0.96 0.88-1.04 88 0.89 0.91 0.70-1.11
Interstitial myositis 21 0.04 0.04 0.02-0.06 2 0.02 0.02 0.01-0.04
Presence of specialist visit on index date or in the year following
IIMs 535 1.05 0.91 0.82-0.99 64 0.65 0.63 0.46-0.79
Dermatomyositis 207 0.41 0.35 0.30-0.40 21 0.21 0.24 0.13-0.35
Polymyositis 374 0.74 0.63 0.56-0.70 49 0.50 0.46 0.32-0.59
Interstitial myositis 27 0.05 0.05 0.03-0.07 8 0.08 0.06 0.02-0.10
Presence of immunosuppressants and/or systemic corticosteroids one year following index date
IIMs 1,761 3.47 3.01 2.86-3.16 304 3.08 3.07 2.70-3.44
Dermatomyositis 725 1.43 1.24 1.14-1.33 103 1.04 1.02 0.80-1.23
Polymyositis 1,146 2.26 1.96 1.84-2.08 225 2.28 2.29 1.97-2.61
Interstitial myositis 133 0.26 0.23 0.19-0.27 32 0.32 0.31 0.20-0.43
Presence of any of the above (combined sensitivity criteria)
IIMs 1,917 3.78 3.29 3.13-3.44 347 3.52 3.50 3.10-3.89
Dermatomyositis 758 1.49 1.29 1.20-1.39 115 1.17 1.13 0.91-1.36
Polymyositis 1,250 2.46 2.14 2.01-2.26 257 2.61 2.62 2.28-2.97
Interstitial myositis 160 0.32 0.28 0.24-0.33 38 0.38 0.36 0.24-0.48
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tension (49.9%) and diabetes (31%), and followed by
IA/A (29.4%). Conversely, medication usage was lower
for nearly all drugs among the Medicaid than the com-
mercial/Medicare cohort. Approximately two-thirds or
more of all patients received a systemic corticosteroid,
followed by a topical corticosteroid. Methotrexate was
received among 26.2% of commercial/Medicare incident
patients and among 14.2% of Medicaid patients.
Azathioprine and hydroxychloroquine were the next
most frequently received, with 14.2% and 12.5% receiv-
ing azathioprine and 14.3% and 9.9% receiving hydroxy-
chloroquine among the commercial/Medicare and
Medicaid populations respectively. Among both cohorts,
Table 4 Characteristics of Myositis Prevalent Patients
(2004–2008)
Commercial and
Medicare patients
Medicaid
patients
n% n %
Myositis (Overall)
1 5,941 100.0% 1,214 100.0%
Dermatomyositis 2,361 39.7% 440 36.2%
Polymyositis 3,443 58.0 771 63.5
Interstitial myositis 585 9.8% 115 9.5%
Year
2
2004 1,865 31.4% 684 56.3%
2005 2,197 37.0% 574 47.3%
2006 2,242 37.7% 355 29.2%
2007 2,562 43.1% 335 27.6%
2008 2,605 43.8% 306 25.2%
Age
18-24 249 4.2% 104 8.6%
25-34 334 5.6% 145 11.9%
35-44 774 13.0% 254 20.9%
45-54 1,403 23.6% 264 21.7%
55-64 1,773 29.8% 248 20.4%
65-74 810 13.6% 118 9.7%
75+ 598 10.1% 81 6.7%
Gender
Female 4,029 67.8% 928 76.4%
Male 1,912 32.2% 286 23.6%
Race/Ethnicity (N, %)
Caucasian .... .... 440 36.2%
African American .... .... 540 44.5%
Hispanic .... .... 81 6.7%
Other/Unknown .... .... 15 1.2%
Region
Northeast 652 11.0% .... ....
North Central 1,668 28.1% .... ....
South 2,416 40.7% .... ....
West 1,167 19.6% .... ....
Unknown 38 0.6 % .... ....
Urbanization
Urban 4,991 84.0% .... ....
Rural 917 15.4% .... ....
Unknown 33 0.6% .... ....
Medicare 1,417 23.9% 460 37.9 %
Fee-for-service (N, %)
Fee-for-service 3,639 61.3 % 850 70.0%
Not fee-for-service 2,302 38.7% 363 29.9%
Unknown 0 0% 1 0.1%
Clinical Conditions
Rheumatoid Arthritis 349 5.9% 114 9.4%
Systemic lupus erythematosus317 5.3% 111 9.1%
Table 4 Characteristics of Myositis Prevalent Patients
(2004–2008) (Continued)
Commercial and
Medicare patients
Medicaid
patients
n% n %
Clinical Conditions
Systemic sclerosis 93 1.6% 34 2.8%
Cushing syndrome 6 0.1% 7 0.6%
Addison's disease 16 0.3% 7 0.6%
Other Inflammatory
Arthritis/Arthropathies
983 16.5% 309 25.5%
Back problems 1074 18.1% 249 20.5%
Dysphagia 213 3.6% 67 5.5%
Hypertension 1578 26.6% 494 40.7%
Diabetes 764 12.9% 299 24.6%
Depression 299 5.0% 191 15.7%
Malignancy 467 7.9% 94 7.7%
Medications on or 365
days after index date
Systemic corticosteriods 4,507 75.9% 881 72.6%
Topical corticosteroids 4,155 69.9% 841 69.3%
Methotrexate 1,887 31.8% 281 23.1%
Azathioprine 993 16.7% 234 19.3%
Hydroxychloroquine 926 15.6% 142 11.7%
Intravenous immunoglobulin 79 1.3% 20 1.6%
Cyclosporine 202 3.4% 17 1.4%
Mycophenolate mofetil 402 6.8% 61 5.0%
Leflunomide 73 1.2% 15 1.2%
Thalidomide 4 0.1 % 0 0.0 %
Cyclophosphamide 83 1.4% 25 2.1%
Tacrolimus 158 2.7% 11 0.9%
Rituximab 48 0.8% 4 0.3%
1Myositis subgroups were not mutually exclusive, and patients could be
assigned to more than one subgroup.
2Yearly counts reflect number of prevalent patients identified in each year and
are not mutually exclusive.
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sporine, leflunomide, thalidomide, cyclophosphamide,
tacrolimus, or rituximab (Table 1).
Incidence rates
As shown in Table 2, overall IIM incidence rates for the
period 2004–2008 for commercial and Medicare supple-
mental groups combined were 4.88 (crude) and 4.27
(adjusted) cases (95% CI, 4.09-4.44) and for Medicaid,
5.2 (crude) and 5.23 (adjusted) cases (95% CI 4.74-5.72)
per 100,000 py. Adjusted incidence rates per 100,000 py
for the same period for each IIM sub-type are as follows:
1.52 (95% CI 1.42-1.63) and 1.70 (1.42-1.97) for DM,
2.46 (2.33-2.59) and 3.53 (3.13-3.94) for PM, and 0.73
(0.66-0.81) and 0.78 (0.58-0.97) for interstitial myositis
for the commercial/Medicare and Medicaid cohorts
respectively.
Adjusted annual incidence for overall IIM ranged from
3.38 (95% CI 3.06-3.71) in 2008 to 5.08 (95% CI
4.61-5.54) in 2005 in the commercial/Medicare database
and from 4.47 (95% CI 3.80-5.15) in 2004 to 6.58 (95%
CI 5.29-8.41) in 2007 in the Medicaid database. Due to
large fluctuations in the size and composition of the de-
nominator associated with variations in MarketScan sub-
scribers (particularly in the Medicaid database),
comparisons over time are not meaningful, and no trend
analysis was undertaken. Crude and adjusted IIM inci-
dence rates were higher among females than males in
both databases. Among commercial/Medicare enrollees,
adjusted incidence among females was 5.38 (5.11-5.66)
and among males was 3.07 (2.85-3.28) per 100,000 py;
LRT χ
2 =6.77, df=1, p =0.009 as shown in Table 2.
Among Medicaid enrollees, rates were 6.68 (6.00-7.36)
for females and 3.67 (2.96-4.37) for males LRT χ
2 =9.08,
df=1, p =0.003 (Table 2). IIM incidence rates by age
group varied between the two cohorts. In the commercial/
Medicare database, the 65–74 years cohort had the highest
rates (9.30 per 100,000 py; 95% CI 8.38-10.22), LRT χ
2
=81.73, df=6 , p<0.001, while in the Medicaid database,
the 55–64 cohort had the highest rates (9.72 per 100,000
py; 95% CI 7.93-11.52), LRT χ
2 =38.69, df=6 , p<0.001
(Table 2).
Sensitivity analyses, which were performed on the
2004–2008 incidence rates for each IIM sub-type,
revealed highly variable incidence rates depending on
the treatment characteristic used as a sensitivity meas-
ure. After the combined-metric sensitivity analysis,
which required a qualifying incident myositis claim in
addition to either a muscle biopsy in the one year prior
to, on, or following the incidence date; or on the inci-
dence date or one year following it, an office visit to a
rheumatologist, dermatologist or neurologist; or a med-
ical or pharmacy claim for an immunosuppressant or
systemic corticosteroid, reported incidence decreased for
all groups. The sensitivity analysis adjusted incidence
rates for overall IIMs were 3.29 cases (vs. 4.27) per
100,000 py for commercial/Medicare and 3.5 cases (vs.
5.23) per 100,000 py for Medicaid (Table 3). In other
words, after applying the combined sensitivity criteria,
the number of identified incident cases per 100,000 py
decreased by 23% for commercial/Medicare and by 33%
for Medicaid.
The combined sensitivity analysis identified between
85% and 87% of incident DM and PM commercial/
Medicare patients as compared to the diagnostic claims
method, and only 38% of those with incident interstitial
myositis. In the Medicaid population the sensitivity ana-
lysis identified 66% of incident DM patients, 74% of inci-
dent PM patients, and 46% of incident interstitial
myositis patients reported as incident using the diagnos-
tic claims method. Among the individual sensitivity cri-
teria, specialist visits on or one year after the incidence
date identified the lowest percentage of incident patients
and immunosuppressants or systemic corticosteroids on
or one year after identified the largest percentage
(Table 3).
Prevalent cohort
We identified 7,155 prevalent patients over the period
2004–2008. Among these patients, 39.1% had DM, 58.9%
Table 5 Annual myositis prevalence (2004–2008): Base
case and sensitivity analysis
Year Commercial
and
Medicare
supplemental
database
(per 100,000
individuals)
Annual
prevalence
95% CI
Medicaid
database
(per 100,000
individuals)
Annual
prevalence
95% CI
Base case
analysis
2004 22.96 21.92-24.01 15.35 14.20-16.50
2005 25.32 24.26-26.38 32.74 30.06-35.42
2006 22.99 22.04-23.94 29.56 26.49-32.64
2007 22.15 21.29-23.00 27.98 24.99-30.98
2008 20.62 19.83-21.41 24.42 21.68-27.15
Sensitivity
analysis
1
2004 19.43 18.47-20.39 12.39 11.36-13.42
2005 21.63 20.66-22.61 28.75 26.24-31.25
2006 19.71 18.82-20.59 23.98 21.21-26.75
2007 19.46 18.65-20.26 22.55 19.86-25.24
2008 18.47 17.72-19.22 19.15 16.73-21.57
1Myositis patients with presence of muscle biopsy on or within one year
before or after prevalence date; specialist visit on or within one year after the
prevalence date; presence of immunosuppressants and/or systemic
corticosteroids on or within one year after index date. Specialist included
rheumatologist, dermatologist, or neurologist.
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patients being prevalent for more than one type of IIM
(Table 4). In the commercial/Medicare database, annual
counts of patients identified as prevalent for interstitial
myositis were low, ranging from 102 in 2004 to 184 in
2006. In the Medicaid database, annual prevalence counts
for DM and interstitial myositis were also low. Prevalent
DM cases ranged from 246 in 2004 (when the Medicaid
database was the largest) to 109 in 2008, and prevalent
interstitial myositis cases ranged from a high of 62 in 2004
Figure 1 a. 2008 myositis prevalence by age: commercial and medicare databases. b. 2008 myositis prevalence by age: medicaid
database.
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results focus on combined IIMs rather than the individual
sub-types.
Prevalent cases were distributed relatively evenly by year
among the commercial/Medicare database, but in the Me-
dicaid database were highest in 2004 followed by 2005,
which reflected the notably higher base population in those
years rather than any observed trend in prevalence over
time. As with incidence, more than 2/3 of the prevalent
population were females (68% among the commercial/
Medicare and 76% among the Medicaid databases). The
mean age of prevalent patients was slightly lower than that
of incident patients. Among commercially insured or Medi-
care enrolled females, the mean age was 54.5 years (SD
15.2) and among males, 55.4 years (SD 14.7). Among Me-
dicaid beneficiaries (a younger group overall), the mean age
for females was 49 years (SD 16.4) and for males was
47.7 years (SD 16.3). As with incidence, Medicaid enrollees
with prevalent IIMs were disproportionately African
American (44.5%) as compared to Caucasian (36.2%) or
Hispanic (6.7%). The regional and urban/rural distribution
of prevalent cases was similar to incident cases in the com-
mercial/Medicare population, with a slightly higher per-
centage in the southern and western regions in the
prevalent cohort than in the incident cohort (Table 4).
These distributions reflected the source databases.
Comorbid conditions identified in the prevalent popu-
lation were similar in proportion to those identified in
the incident population with hypertension, back pro-
blems, other inflammatory arthritis/arthropathies, and
diabetes the most common conditions among both the
commercial/Medicare and Medicaid cohorts. Medication
usage for nearly all reported drugs was slightly higher
among the prevalent than the incident populations for
both databases (Table 4).
Annual prevalence over the study period of 2004–2008
ranged from 20.62 to 25.32 per 100,000 for commercial/
Medicare enrollees (83% of prevalent cases) and from
15.35 to 32.74 for Medicaid enrollees (Table 5). After sen-
sitivity analysis, the number of reported annual prevalent
patients decreased to 18.47 in 2004 and 21.63 in 2008 for
the commercial/Medicare cohort, a difference of 10% to
15%. For the Medicaid cohort, after applying the com-
bined sensitivity criteria, annual prevalence dropped to
12.39 in 2004 to 28.75 in 2005, reflecting declines in
prevalence of 12% to 22%.
Prevalence was higher among females than males in
all years and for both commercial/Medicare and Medic-
aid databases. For example, in 2008, the most recent
year for which prevalence data were available, female
prevalence per 100,000 by age group varied from 11.23
among those 25–34 years of age to 54.87 among those
65–74 years of age, while for males prevalence ranged
from 3.58 among 18–24 year olds to 28.83 among 65–
74 year olds in the commercial/Medicare population
(Figure 1a). Similarly, among the Medicaid population,
prevalence in 2008 ranged from 11.7 in the 18–24 years
cohort to 48.27 in the 45–54 years cohort among
females and from 4.61 to 22.99 in the same age groups
among males (Figure 1b). In 2008, prevalence for DM
was 9.18 per 100,000 (13.7 in females, 4.03 in males), for
PM was 11.19 (12.2 in females and 8.9 in males), and for
interstitial myositis was 1.12 (1.46 in females, 0.74 in
males) in the commercial/Medicare population (results
not shown). For 2008, prevalence for DM was 8.7 per
100,000 (11.24 in females, 3.26 in males), for PM was
15.48 (18.15 in females and 9.77 in males), and for inter-
stitial myositis was 1.04 (0.82 in females, 1.5 in males) in
the Medicaid population (results not shown). Annual
observed counts of DM, PM, and in particular, intersti-
tial myositis were rare in the Medicaid population, with
in some cases two, one, or zero observations in a given
age/gender category. Thus annual DM, PM, and intersti-
tial myositis prevalence in the Medicaid population was
subject to instability due to low counts.
Discussions
IIMs are a rare condition, and little is known about the
extent of their incidence and prevalence in the U.S.
population. In this study, we used the MarketScan Com-
mercial, Medicare, and Medicaid administrative claims
databases to identify incidence and prevalence of IIMs
based on medical claims with an ICD-9-CM diagnosis
indicating DM, PM, or interstitial myositis. Administra-
tive claims analyses, such as the one performed here,
have the benefit of data contributed by very large popu-
lations seeking medical care, which can be used to iden-
tify rare conditions and shed additional light into
incidence and prevalence. The limitation of these meth-
ods is the flip side of the benefit coin, in that unless
patients seek care for their IIM, they will not be cor-
rectly identified as incident or prevalent. In addition,
misdiagnosis or recording errors can result in under- or
over-reporting of the condition. Another limitation in
using administrative claims databases for identifying inci-
dence and prevalence is that the results are sensitive to the
methods used to identify the population denominator.
Due to the dynamic nature of the employer-based and
Medicaid administrative claims databases used here, the
annual values are most informative as snapshots provid-
ing a range of estimates among a fluctuating population,
rather than indicative of trends in incidence or preva-
lence of myositis in the U.S. population. Another consid-
eration particular to employer-based databases is that
employees with chronic conditions may be less likely to
change employers and risk changes to their healthcare
coverage, and therefore may stay in the data longer than
other employees at the same employer.
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ods (1 inpatient or 2 outpatient claims for PM, DM, or
interstitial myositis) in another U.S. managed care admin-
istrative claims database [19] reported notably higher inci-
dence of IIMs than the 0.1 to 1 per 100,000 py reported
in community-based studies using smaller populations
[2,10-15]. This study identified age- and sex-adjusted inci-
dence rates of 4.27 (commercial/Medicare) and 5.23 (Me-
dicaid) per 100,000 py for the period 2004–2008, while
Furst et al. [19] reported adjusted incidence rates of 6.57
(95% CI, 6.20–6.94) per 100,000 py for combined IIMs.
For DM, we identified adjusted incidence rates of 1.52 and
1.70 per 100,000 py in the commercial/Medicare and Me-
dicaid databases respectively, which were relatively com-
parable to the 1.38 per 100,000 py reported by Furst et al.
[19]. Incidence rates for PM were also comparable at 2.46
(commercial/Medicare) and 3.53 (Medicaid) in this study
versus 3.79 per 100,000 py in Furst et al [19]. These rates
were similar to the prevalence of PM of 3.45 per 100,000
py identified by Wilson et al. [10]. Interstitial myositis var-
ied among the two studies, in that it was the least com-
mon of the three types of IIM, with adjusted incidence of
0.73 and 0.78 per 100,000 py in the two databases com-
pared to 1.69 per 100,000 py reported in Furst et al. [19],
in which DM rather than interstitial myositis was the least
common type of myositis. Due to very low counts of inter-
stitial myositis, along with limited consistent clinical infor-
mation about the condition and its diagnosis, incidence
and prevalence for that sub-type should be interpreted
with caution.
In contrast to incidence estimates, the prevalence of
IIMs identified by medical claim (20.62 to 25.32 per
100,000 py in commercial/Medicare and 15.35 to 32.74 in
Medicaid) in this study is quite comparable to that identi-
fied using a contemporary administrative claims database
in Quebec (combined DM and PM annual prevalence in
2003 of 21.5 (95% CI 19.4-23.9) per 100,000 py [16]. The
prevalence of IIMs identified in this study is, however,
somewhat higher than prevalence of combined DM, PM
and interstitial myositis given in Furst et al. [19] of 9.54 in
2003 and 13.61 in 2008, albeit the lower prevalence in
Furst et al. could be associated with a younger population
(9% of prevalent cases were≥65 years in their IIM cohort
vs. 24%≥65 years in the commercial/Medicare and 16% of
prevalent cases in the Medicaid IIM cohorts). Notably, all
three administrative claims studies reported annual preva-
lence that was nearly 2- to 6-fold higher than that
reported in one earlier study from 2003 [17]. It is possible
that with increased awareness of IIMs, the condition may
be increasingly recognized and diagnosed, and thus show-
ing up more frequently in administrative claims databases
over the past decade than in previous decades.
When the 2004–2008 age- and sex-adjusted incidence
rates for the two databases are projected to the U.S.
population ages 18 years and older, the expected number
of incident cases per year ranges from 8,919 to 10,937
(based on the commercial/Medicare and Medicaid inci-
dence rates respectively, standardized to the 2000 U.S.
Census). Using the combined sensitivity analysis (e.g., IIM
incidence along with one or more of the three sensitivity
criteria), the expected number of incident cases per year
among adults in the U.S. ranges from 6,871 (commercial/
Medicare incidence rates) to 7,312 (Medicaid incidence
rates).
Extrapolating the annual prevalence of persons seeking
medical care for IIMs reported here to the U.S. population
(as of the 2000 U.S. Census) aged 18 years and older from
the commercial/Medicare cohort results in a range of an
estimated 43,000 to 53,000 treated cases per year, or, after
e m p l o y i n ga n yo n eo ft h et h r e es ensitivity criteria, an esti-
mated 38,000 to 45,000 treated cases per year. If the Medic-
aid annual prevalence is used, estimated annual U.S. IIM
prevalence ranges from approximately 32,000 to 68,000
using IIM claims only, or 26,000 to 60,000 treated cases
using any of the three sensitivity criteria.
This study is unique in its incorporation of three payer
groups: commercially insured, Medicare enrollees (with
employer paid supplemental insurance), and Medicaid
enrollees. The different incidence and prevalence identified
in the commercial/Medicare versus Medicaid populations
in this analysis may be a result of differences in patients’
healthcare-seeking behaviors as well as in reimbursement
and practice patterns rather than the underlying difference
in disease incidence and prevalence among the two popula-
t i o n s .T h er e l a t i v es i m i l a r i t yi np r e v a l e n c ea n di n c i d e n c e
identified in separate studies conducted in different admin-
istrative claims databases indicates that these variations are
common in these types of databases. Another consideration
unique to the current study is the high incidence and
prevalence among African Americans identified in the Me-
dicaid database. Since race/ethnicity is unknown in the
commercial and Medicare cohorts, it is unknown to what
extent differences in racial composition between the two
cohorts may influence the observed incidence and preva-
lence of myositis. Additional studies of IIM incidence and
prevalence by race/ethnicity are needed.
The incidence and prevalence estimates reported here are
in the range of those reported in other studies using admin-
istrative claims databases. Like those studies, the estimates
reported here are based on the presence of a medical claim
with the ICD-9-CM diagnoses of interest and are a function
of individuals seeking medical care and physician reporting
of diagnosis. This study used an algorithm to exclude rule-
out diagnoses; nevertheless, administrative claims are not a
substitute for a complete medical record for the study
population and thus mis-diagnoses are possible. Since a
one year “clean” period was required to qualify as incident,
incidence may have been over-estimated if patients already
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preceding year. In addition, prevalence was expected to be
u n d e r - e s t i m a t e da si tw a sd e f i n e db ye v i d e n c eo fa
qualifying medical claim with an IIM diagnosis in each year.
Patients with the condition who did not seek medical care
in a given year would not be captured in the prevalence
estimates. Finally, employer turnover, miscoding and mis-
diagnosing, care seeking behavior, and fluctuations in data-
base membership over time can influence the results.
Further studies are needed to confirm the incidence and
prevalence of IIM.
Conclusions
Among 2,990 incident IIM patients between 2004 and
2008, overall adjusted IIM incidence for 2004–2008 for
commercial and Medicare supplemental groups com-
bined were 4.27 cases per 100,000 py, and for Medicaid
were 5.23 cases per 100,000 py. The highest incidence
among disease sub-types was for PM, at 2.46 (commer-
cial/Medicare) and 3.53 (Medicaid) new cases per
100,000 py. Annual IIM prevalence ranged from 20.62 to
25.32 per 100,000 for commercial/Medicare (83% of
prevalent cases) and from 15.35 to 32.74 for Medicaid.
Although this study found higher IIM incidence than
historically reported based on smaller, localized popula-
tions, the similarity of the findings of the current study
with others in the literature using administrative claims
databases suggests that IIM incidence in the U.S. popu-
lation is in the range of 3 to 7 new cases per 100,000 py
and that prevalence as measured by claims for IIM treat-
ment is in the range of 32,000 to 68,000 per year. Future
studies using alternate administrative claims databases
will be helpful in narrowing down the range of incidence
and prevalence estimates, and additional analyses of the
cohorts identified as incident and prevalent using chart
review would be beneficial in confirming IIM diagnoses,
particularly for the three sub-types.
Endnotes
aImmunosuppressants included methotrexate, azathiopr-
ine, hydroxychloroquine, intravenous immunoglobulin,
cyclosporine, mycophenolate mofetil, leflunomide, thalido-
mide, cyclophosphamide, tacrolimus, and rituximab.
bMuscle biopsy codes included ICD-9-CM Procedure
83.21 or CPT codes 10021, 10022, 20200, 20205, 20206,
21550, 21925, 23066, 24066, 25066, 27041, 27324, or 27614.
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